Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases by Guerreiro, R et al.
lable at ScienceDirect
Neurobiology of Aging 38 (2016) 214.e7e214.e10Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingGenome-wide analysis of genetic correlation in dementia with Lewy
bodies, Parkinson’s and Alzheimer’s diseases
Rita Guerreiro a,2, Valentina Escott-Price b,2, Lee Darwent a, Laura Parkkinen c, Olaf Ansorge c,
Dena G. Hernandezd,e, Michael A. Nalls d, Lorraine Clark f,g, Lawrence Honig f,g,
KarenMarder f,h,WiesjevanderFlier i,HenneHolstege i,EvaLouwersheimer i,AﬁnaLemstra i,
Philip Scheltens i, Ekaterina Rogaeva j, Peter St George-Hyslop j,k, Elisabet Londos l,
Henrik Zetterbergm,a, Sara Ortega-Cuberon,o, Pau Pastor n,o,p, Tanis J. Fermanq,
Neill R. Graff-Radford r, Owen A. Ross s, Imelda Barber t, Anne Braae t, Kristelle Brown t,
Kevin Morgan t, Walter Maetzler u, Daniela Berg u, Claire Troakes v, Safa Al-Sarraj v,
Tammaryn Lashleyw, Yaroslau Comptaw,x, Tamas Reveszw, Andrew Leesw, Nigel J. Cairns y,
Glenda M. Halliday z,aa, David Mannbb, Stuart Pickering-Brownbb, John Powell cc,
Katie Lunnondd, Michelle K. Lupton cc, International Parkinson’s Disease Genomics
Consortium (IPDGC)1, Dennis Dickson s, John Hardyee, Andrew Singletond, Jose Bras a,*
aDepartment of Molecular Neuroscience, Institute of Neurology, UCL, London, UK
bMRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK
cNufﬁeld Department of Clinical Neurosciences, Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, UK
d Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD, USA
eGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
f Taub Institute for Alzheimer Disease and the Aging Brain, Columbia University, New York, NY, USA
gDepartment of Pathology and Cell Biology, Columbia University, New York, NY, USA
hDepartment of Neurology, Columbia University, New York, NY, USA
iDepartment Of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
jDepartment of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
kCambridge Institute for Medical Research, and Cambridge National Institute of Health Research Biomedical Research Unit in Dementia, University of
Cambridge, Cambridge, UK
lClinical Memory Research Unit, Institute of Clinical Sciences Malmö, Lund University, Lund, Sweden
mClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at
the University of Gothenburg, Gothenburg, Sweden
nNeurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, (CIMA), University of Navarra, Pamplona, Spain
oCIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain
pMemory and Movement Disorders Units, Department of Neurology, University Hospital Mutua de Terrassa, University of Barcelona School of Medicine,
Terrassa, Barcelona, Spain
qDepartments of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA
rDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA
sDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
t Translation Cell SciencesdHuman Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK
uHertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, and DZNE, German Center
for Neurodegenerative Diseases, Tuebingen, Germany
vMRC London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Department of Clinical Neuroscience, King’s College London, London, UK
wQueen Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
x Parkinson’sDisease&MovementDisordersUnit,NeurologyService,ClinicalNeuroscienceInstitute(ICN),HospitalClínic/UniversityofBarcelona/IDIBAPS,Barcelona,Spain
yDepartment of Neurology, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA
zNeuroscience Research Australia, Sydney, Australia
aa School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia
bb Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
ccDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
dd Institute of Clinical and Biomedical Science, University of Exeter Medical School, University of Exeter, Exeter, UK
eeReta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK* Corresponding author at: Department of Molecular Neuroscience, Institute of Neurology, University College of London, 8-11 Queen Square, DRC, Box 16, London, WC1N
3AR, UK. Tel.: þ44 203 448 3936.
E-mail address: j.bras@ucl.ac.uk (J. Bras).
1 A complete list of the IPDGC members is listed in the Supplementary Material.
2 Equally contributing authors.
0197-4580/ 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.neurobiolaging.2015.10.028
R. Guerreiro et al. / Neurobiology of Aging 38 (2016) 214.e7e214.e10214.e8a r t i c l e i n f o
Article history:
Received 13 October 2015
Received in revised form 27 October 2015
Accepted 28 October 2015
Available online 2 November 2015
Keywords:
Dementia with Lewy bodies
Alzheimer’s disease
Parkinson’s disease
Genetic correlationa b s t r a c t
The similarities between dementia with Lewy bodies (DLB) and both Parkinson’s disease (PD) and Alz-
heimer’s disease (AD) are many and range from clinical presentation, to neuropathological characteris-
tics, to more recently identiﬁed, genetic determinants of risk. Because of these overlapping features,
diagnosing DLB is challenging and has clinical implications since some therapeutic agents that are
applicable in other diseases have adverse effects in DLB. Having shown that DLB shares some genetic risk
with PD and AD, we have now quantiﬁed the amount of sharing through the application of genetic
correlation estimates, and show that, from a purely genetic perspective, and excluding the strong as-
sociation at the APOE locus, DLB is equally correlated to AD and PD.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
As we move toward an era where precision medicine becomes a
reality, being able to conﬁdently differentiate between closely
related diseases is fast becoming a key priority. This is even more
relevant when therapeutic approaches from one disease have
negative effects when used in patients from another, as is the case
in dementia with Lewy bodies (DLB) where neuropsychiatric and
dysautonomic features can be worsened by dopaminergic agents
used in Parkinson’s disease (PD; Zweig and Galvin, 2014).
DLB is probably one of the most underserved common disorders
and much of this stems from the fact that it is a disease for which a
clinical diagnosis is a particularly difﬁcult one to make as DLB can
be misdiagnosed as Alzheimer’s disease (AD) when starting with
cognitive impairment or as PDwhen presenting with parkinsonism,
and in turn PD can be easily mistaken as DLB if parkinsonism is
overlooked. There are numerous shared aspects between DLB and
the other more common neurodegenerative diseases PD and AD.
This is not only true at the clinical level (particularly in the case of
DLB and PD, to the point that an artiﬁcial and arbitrary “one-year-
rule” in terms of the timing between parkinsonism and dementia
has been needed to delineate them), but also, to some extent, at the
pathological level, where Lewy bodies are a common characteristic
of both DLB and PD, and beta-amyloid plaques and tau-positive
neuroﬁbrillary tangles, hallmarks of AD, often coexist in DLB and
PD brains leading to the suggestion of a synergism between these
pathologies (Compta et al., 2011; McKeith et al., 2005).
It is key that we have a better understanding of the molecular
mechanisms occurring in DLB, not only because this is pivotal in-
formation for novel therapies to be developed for this disease, but
also because it will help us gain a better understanding of PD,
particularly when associating dementia, and AD.
We have recently performed a large-scale genetic analysis in
DLB that showed similarities in common genetic risk between this
disease, PD, and AD (Bras et al., 2014) using NeuroX, a genome-wide
genotyping array (Nalls et al., 2015). To better understand and
quantify these similarities we have now estimated the proportion
of variance explained by all single nucleotide polymorphisms of the
DLB cohort, and of independent AD and PD cohorts of similar size.
We then performed a bivariate restricted maximum likelihood
analysis of the genetic relationship matrix, to quantify the genetic
covariance between pairs of diseases.2. Methods
Details of the DLB cohort have been published previously (Bras
et al., 2014). We used a cohort of 804 European PD cases and a
cohort of 959 clinically diagnosed European AD cases, as well as2806 European and North-American controls, genotyped on Illu-
mina’s NeuroX. The PD samples are a UK-only subset of the previ-
ously published PD and control dataset (Nalls et al., 2014). The AD
cases were diagnosed as either deﬁnite or probable AD according to
National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s disease and Related Disorders As-
sociation (McKhann et al., 1984), and the Consortium to Establish a
Registry for Alzheimer’s disease guidelines (Mirra et al., 1991). All
samples used in this study were received with informed consents
approved by the local Ethics Committees (Table 1).
Following standard raw data quality control procedures, which
included removing variants with GenTrain scores (a metric to assess
genotyping quality) lower than 0.9 and samples with call rate lower
than90% (meaning that samples thathad less than90%of themarkers
genotyped were excluded), we removed markers that had a geno-
typing rate of>10% and aminor allele frequency of<3%. To generate
covariates for the analysis, multidimensional scaling was used to
quantify genetic distances between members of the entire cohort.
After estimating the genetic relationship matrix between pairs
of individuals, we performed a bivariate restricted maximum like-
lihood analysis on that matrix, as implemented in the software
genome-wide complex trait analysis (Lee et al., 2012; Yang et al.,
2010) using the ﬁrst 2 principal components from multidimen-
sional scaling.
For each comparison the control population was randomized
and 1403 controls were assigned to each disease. The analysis be-
tween DLB and AD was then repeated excluding markers in the
APOE region.3. Results
When using the entire array content, after quality control pro-
cedures, the estimates for the proportion of variance explained by
all single nucleotide polymorphisms for DLB was 0.31 (SE  0.03),
for AD was 0.6 (SE  0.05), and for PD was 0.28 (SE  0.05). When
excluding the APOE region, the estimates were 0.22 (SE 0.03), 0.42
(SE  0.05), and 0.28 (SE  0.05), for DLB, AD, and PD. The decrease
seen in DLB and AD reﬂect the strong and robust association of the
APOE locus in these diseases.
When comparing pairs of diseases for genetic correlation (i.e.,
estimating the additive genetic effect i.e., shared between pairs of
traits), the highest score was obtained for the AD/DLB pair (0.578,
SE  0.075). The comparison between PD or DLB yielded a cor-
relation score of 0.362 (SE  0.107). Both scores were highly
signiﬁcant with p-values of 1.1  1012 and 7.1  104, respec-
tively. As a control experiment, we compared AD/PD and ob-
tained a signiﬁcantly lower score 0.08 (SE  0.101)
(p-value ¼ 0.006, with the most conservative estimate provided
Table 1
Samples included in the study
Trait Total cases Pathologically conﬁrmed cases
DLB 788 667
AD 959 113
PD 804 0
Key: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PD, Parkinson’s
disease.
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in R, a test of signiﬁcance for the difference between 2 correla-
tions based on dependent groups with 1 variable in common),
that does not deviate from the null hypothesis of no correlation
(p-value ¼ 0.39).
Given the strong effect from APOE in AD and DLB, we have
performed the same analysis excluding this locus in these 2 cohorts
and obtained a correlation score for AD/DLB_NO_APOE (0.332 
0.106) that is not statistically different from the PD/DLB correlation
(0.362  0.107) (p-value ¼ 0.761, using the same test as mentioned
previously). The AD/DLB_NO_APOE correlation is still highly sig-
niﬁcant 1.8  103 (Table 2).
4. Discussion
We have previously described that DLB shares genetic risk de-
terminants with both PD and AD. Here we quantify that overlap by
showing that these diseases are, in fact, correlated from a purely
genetic perspective.
The DLB cohort is the largest reported so far and a majority of
these cases are neuropathologically conﬁrmed (85%), which greatly
increases the diagnostic accuracy (Bras et al., 2014). The numbers of
PD and AD cases in this study are small, particularly when in
comparison with other published datasets. We should note, how-
ever, that the fact that we fully replicate the phenotypic variance
associated with all types of PD from large meta-analysis studies
(Keller et al., 2012), suggests these cohorts are representative, and
not substantially underpowered for this type of analysis. In addi-
tion, our data shows no genetic correlation between PD and AD
(correlation ¼ 0.08, SE  0.101, p-value ¼ 0.39 when correlation is
ﬁxed at 0), a result that replicates previous independent ﬁndings
(Moskvina et al., 2013).
It should be noted that although being a genome-wide array,
NeuroX is not a completely unbiased genotyping platform. A pro-
portion of the variants assayed in this array were included because
they were known to be involved in these diseases. Because of this,
some of these values may be inﬂated, however, for the purposes of
determining genetic correlation, and comparing between pairs of
diseases, this should have no discernible effect.
That DLB seems to share approximately the same amount of
genetic risk determinants with PD and AD ﬁts with our under-
standing of this disease, given the clinical and neuropathological
overlap. Although not assessed in this work, it would be interesting
to test if these correlations reﬂect quantitative pathology (e.g.,
would excluding DLB cases with prominent AD-related pathology
reduce the correlation score between DLB and AD).Table 2
Genetic correlation scores between pairs of diseases
Trait1 Trait2 Genetic correlation SE p-value
AD DLB 0.578 0.075 1.1  1012
PD DLB 0.362 0.107 7.1  104
AD PD 0.08 0.101 0.39
AD DLB_NO_APOE 0.332 0.106 1.8  103
Key: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PD, Parkinson’s
disease; SE, standard error.5. Conclusions
This is the ﬁrst study to look at genetic correlation between DLB,
PD, and AD. Despite using small cohorts, we show that these data
replicate previously published results. We also show that DLB
shares approximately the same amount of genetic determinants
with PD as it does with AD, when the APOE locus is excluded. These
results show us that, from a mechanistic standpoint, DLB is a
different, but highly related disease to both AD and PD. They further
emphasize the need for more studies in DLBdthis is a greatly un-
derappreciated disease and these data strongly support this fact.
Fully dissecting the genetic architecture of DLB will allow us to gain
a better understanding of not just one but all 3 diseases. In addition,
these data also show that we should gradually move from the
current model of binary diagnosis to a more quantitative one.
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